Patents by Inventor Erik Wallstrom

Erik Wallstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB
    Publication number: 20240150485
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS).
    Type: Application
    Filed: June 8, 2023
    Publication date: May 9, 2024
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB
    Publication number: 20220081488
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Application
    Filed: October 6, 2021
    Publication date: March 17, 2022
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN
    Publication number: 20220016076
    Abstract: The present invention relates to siponimod (BAF312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.
    Type: Application
    Filed: June 2, 2020
    Publication date: January 20, 2022
    Inventors: Eric Legangneux, Erik Wallström, Philippe Michel Rene Bouillot, Emeric Reynaud, Frank Dahlke
  • Regimens and methods of treating multiple sclerosis using ofatumumab
    Patent number: 11161909
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • Dosing Regimen of Siponimod
    Publication number: 20200316021
    Abstract: The present disclosure relates to a novel dosing regimen for the administration of siponimod or pharmaceutically acceptable co-crystals or salts thereof, in the treatment of stroke, in particular ischemic stroke, e.g. acute ischemic stroke.
    Type: Application
    Filed: September 27, 2018
    Publication date: October 8, 2020
    Inventors: Jang-Ho Cha, Frank Dahlke, Anne Gardin, Eric Legangneux, Carl Joseph Malanga, III, Kasra Shakeri-Nejad, Erik Wallstrom, Christian Wolf
  • Dosing Regimen of Siponimod
    Publication number: 20200306222
    Abstract: The present disclosure relates to a novel dosing regimen for the administration of siponimod or pharmaceutically acceptable co-crystals or salts thereof, in the treatment of stroke, in particular intracerebral hemorrhage (ICH).
    Type: Application
    Filed: September 27, 2018
    Publication date: October 1, 2020
    Inventors: Jang-Ho Cha, Frank Dahlke, Anne Gardin, Eric Legangneux, Carl Joseph Malanga, III, Kasra Shakeri-Nejad, Erik Wallstrom, Christian Wolf
  • REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB
    Publication number: 20190177424
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 13, 2019
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN
    Publication number: 20190054065
    Abstract: The present invention relates to siponimod (BAF312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Eric Legangneux, Erik Wallström, Philippe Michel Rene Bouillot, Emeric Reynaud, Frank Dahlke
  • SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN
    Publication number: 20170027907
    Abstract: The present invention relates to siponimod (BAF312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.
    Type: Application
    Filed: April 8, 2015
    Publication date: February 2, 2017
    Inventors: Eric Legangneux, Erik Wallström, Philippe Michel Rene Bouillot, Emeric Reynaud, Frank Dahlke